Loading

Original Research Open Access
Volume 6 | Issue 2 | DOI: https://doi.org/10.33696/cardiology.6.082

Allopurinol for Prevention of Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Intervention: A Randomized-Controlled Trial

  • 1Cardiology Department, Cairo University, Cairo, Egypt
+ Affiliations - Affiliations

Corresponding Author

Kareem Mahmoud, dr.kareem215@yahoo.com

Received Date: June 17, 2025

Accepted Date: October 21, 2025

Abstract

Background: Contrast-induced acute kidney injury (CI-AKI) is a potential complication following percutaneous coronary intervention (PCI), particularly in patients with pre-existing kidney conditions. Previous research has identified hyperuricemia as a predictor for CI-AKI. Allopurinol, a medication commonly used to manage hyperuricemia, also possesses anti-inflammatory properties. This study aims to assess the impact of adding allopurinol to hydration therapy on CI-AKI incidence in patients undergoing PCI.

Results: We enrolled 107 patients undergoing PCI with moderate to high Mehran risk scores; Participants were randomly assigned to either an allopurinol group (n=52) or a control group (n=55). The allopurinol group received 300 mg of allopurinol 24 hours before and one hour before PCI, along with intravenous normal saline at 1 ml/kg/hour. The control group received conventional hydration only. Serum creatinine and urea levels were measured before and 48 hours after the procedure. An increase in serum creatinine by ≥25% or ≥0.5 mg/dL 48 hours after PCI was used to detect contrast-induced acute kidney injury (CI-AKI).
The mean age of the patients was 59.8±8.9 years, with 63% being male. The baseline Mehran risk score was 9.5±3.0. Baseline characteristics, including age, gender, risk factors, kidney function, and uric acid levels, were similar between the two groups. CI-AKI occurred in 5 patients (9.6%) in the allopurinol group and 15 patients (27.3%) in the control group (P=0.017). No significant difference was found in serum uric acid levels between patients with and without CI-AKI (7.2±2.8 mg/dL vs. 6.8±2.0 mg/dL, p-value: 0.49).

Conclusion: Our results suggest that allopurinol may reduce CI-AKI incidence beyond its hypouricemic effect following elective PCI in patients with moderate to high Mehran risk score. However, further large-scale, multi-center studies are needed to confirm these findings.

Keywords

Allopurinol, Contrast-induced acute kidney injury, Coronary artery disease, Percutaneous coronary intervention

Author Information X